newsfilter
← Latest News
Business Wire·

BitNile Holdings Announces That Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

ALZN002 is believed to be the first autologous dendritic cell-based active immunotherapy vaccine candidate to be tested in humans to treat Alzheimer's BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company